NF1 and neoplasm: For instance, Liu et al. engineered G47Δ to express a dominant-negative FGFR (bG47Δ-dnFGFR), which significantly enhanced its antitumor and antiangiogenic efficacy in NF1-associated neural tumors by simultaneously targeting tumor cells and tumor vasculature, without impairing viral replication [115].